TIDMAMP
RNS Number : 6005F
Amphion Innovations PLC
29 July 2016
Amphion Innovations plc
("Amphion" or "the Company")
Results of AGM and Directorate Change
London and New York, 29 July 2016 - Amphion Innovations plc
(AIM: AMP), the developer of medical, life science, and technology
businesses, today announces that all resolutions were passed at the
Annual General Meeting, which was held on Wednesday 27 July
2016.
Included in the resolutions were the appointments to the Board
of Mr. Richard Mansell-Jones as Director and Chairman and Mr. Paul
Kennedy as Non-executive Director, effective immediately.
Richard Mansell-Jones is a former Non-executive Chairman of
Amphion, and has great experience of public company leadership and
governance. Mr. Mansell-Jones was Non-executive Chairman of Brown,
Shipley & Co. Limited from 1992 until 2003. From 1988 until
2000 he was Executive Chairman of J. Bibby & Sons PLC
(subsequently Barloworld PLC); from 1992 until 2005 he was a
Non-executive Director of Standard Bank London Limited (now
Standard Bank PLC), where latterly he served as Chairman of the
Audit Committee, and from 2001 until 2006 he was Non-executive
Chairman of Millfield Group plc. Furthermore, Mr. Mansell-Jones is
a Non-Executive Director of a number of charities, including
Burlington Magazines Publications Limited and World Monuments Fund
Britain Limited. After reading Literae Humaniores at Worcester
College, Oxford, he was articled to Price Waterhouse & Co,
becoming a Chartered Accountant, before joining N. M. Rothschild
& Sons in 1968.
Paul Kennedy has an extensive career in the pharmaceutical
industry, occupying senior management positions with major
pharmaceutical companies as well as working and investing as an
entrepreneur in smaller biotechnology companies. Mr. Kennedy worked
as a Marketing Director for seven years at Abbott France and Boots,
both in the UK and France, before joining Novo Nordisk France,
where he was President for 15 years. Having left Novo Nordisk in
1994, Mr. Kennedy set up his own pharmaceutical company,
Laboratoires Murat, which was purchased by Fuisz Technologies Ltd,
a Nasdaq-listed drug delivery company, three years later. Mr.
Kennedy then worked as Executive Vice President, Operations for
Fuisz Technologies in Paris, adding acquisitions in France, Germany
and Italy, before the business was sold to Shire plc in 1999. From
1999 to 2004 he worked as an Independent Consultant in the
pharmaceutical industry, and in 2004, Mr. Kennedy became President
of International Operations at AIM-listed medical diagnostics
company Cozart plc. In 2007, Mr. Kennedy became a controlling
shareholder and Director of US listed IVAX Diagnostics, Inc, which
was subsequently sold to Transasia Bio-Medicals Ltd, India's
largest diagnostics company, in September 2010. Mr. Kennedy is
currently a director of Venn Life Sciences Holdings plc and has
participated as an investor in several AIM IPOs.
Save as disclosed below, there are no further details required
to be disclosed pursuant to schedule 2(g) of the AIM rules.
Richard Mansell Mansell-Jones, age 76, is currently a director
of, or during the past five years has been a director of, the
following companies:
Current directorships Past directorships held
and partner positions within the last 5 years
British Sporting Arts n/a
Trust
Burlington Magazine Foundation
Burlington Magazine Publications
Limited (The)
World Monuments Fund Britain
Limited
Mr. Mansell-Jones' beneficial interests in the Company amounts
to 3,785,530 ordinary shares in the Company ("Ordinary Shares"),
representing 1.92% of the Company's issued share capital,
GBP39,677.30 of convertible unsecured promissory notes and 79,354
warrants over Ordinary Shares.
Heim Gallery (London) Limited entered receivership in June 1991
and was dissolved on 12 November 2002, during which time Mr.
Mansell-Jones was an appointed director.
Millfield Group plc, where Mr. Mansell-Jones was a director
until 25 August 2006, entered into administration on 13 July 2006
before entering into a creditors' voluntary liquidation on 29 May
2007, and was dissolved on 20 June 2012.
Paul Francis Kennedy, age 71, is a director of Venn Life
Sciences plc, and currently holds no beneficial interests in the
Company.
For further information please contact:
Amphion Innovations
Charlie Morgan
+1 212 210 6224
Yellow Jersey PR
Charles Goodwin / Dominic Barretto
+44 (0)7747 788 221
Panmure Gordon Limited (Nominated Adviser and Corporate
Broker)
Freddy Crossley / Duncan Monteith (Corporate Finance)
Charlie Leigh-Pemberton (Corporate Broking)
+44 (0)20 7886 2500
Northland Capital Partners Limited (Joint Corporate Broker)
Patrick Claridge / David Hignell (Corporate Finance)
John Howes (Corporate Broking)
+44 (0)20 3861 6625
Plumtree Capital Limited (Financial Adviser)
Stephen Austin
+44 (0)20 7183 2493
+646 568 7502
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) No 596/2014.
About Amphion Innovations plc
Amphion Innovations is a developer of medical, life science and
technology businesses.
We use our extensive experience in company building to invest
and build shareholder value in high growth companies in the US and
UK. Amphion has significant shareholding in 7 Partner Companies
developing proven technologies targeting substantial commercial
marketplaces. The Amphion model has been refined to optimise the
commercialisation of patents and other intellectual property within
the Partner Companies. The Partner Companies collectively own or
control over 200 separately identified pieces of intellectual
property, a number which grows rapidly each year.
On the web: www.amphionplc.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGDDGDRSGDBGLI
(END) Dow Jones Newswires
July 29, 2016 02:01 ET (06:01 GMT)
Amphion Innovations (LSE:AMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amphion Innovations (LSE:AMP)
Historical Stock Chart
From Apr 2023 to Apr 2024
